Selected Publications
Since 2020
Shaw TI, Wagner J, Tian L, Wickman E, Poudel S, Wang J, Paul R, Koo SC, Lu M, Sheppard H, Fan Y, O'Neil F, Lau CC, Zhou X, Zhang J, Gottschalk S. Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression. Nat Commun 2024 May 3;15(1):3732. doi: 10.1038/s41467-024-47649-y
Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, Grilley B, Lapteva N, Gee A, Dotti G, Bao R, Salem AH, Wang T, Brenner MK, Heslop HE, Wels WS, Hicks MJ, Gottschalk S, Ahmed N. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer 2024 Apr 24. doi: 10.1038/s43018-024-00749-6
Bell M, Lange S, Sejdiu BI, Ibanez J, Shi H, Sun X, Meng X, Nguyen P, Sutton M, Wagner J, KC A, Langfitt D, Patil SL, Tan H, Pandey RV, Li Y, Yuan Z-F, Anido AA, Ho M, Sheppard H, Vogel P, Yu J, Peng J, Chi H, Babu MM, Krenciute G, Gottschalk S. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling. Nat Biomed Eng 2023 Nov 30. doi: 10.1038/s41551-023-01143-w
Chockley PJ, Ibanez-Vega J, Krenciute G, Talbot LJ, Gottschalk S. Synapse-tuned CARs enhance immune cell anti-tumor activity. Nat Biotechnol 2023 Feb 2. doi: 10.1038/s41587-022-01650-2
Yan K-K, Condori J, Ma Z, Ju B, Ding L, Dhungana Y, Palmee LE, Langfitt DM, Metais JM, Ferrarra F, Throm R, Shi H, Risch I, Bhatara S, Shaner B, Lockey TD, Talleur AC, Easton J, Meagher MM, Puck JM, Cowan MJ, Zhou S, Mamcarz E, Gottschalk S*, Yu J* (*shared senior authorship). Integrome signatures of lentiviral gene therapy for SCID-X1 patients. Sci Adv 2023 Oct 6;9(40):eadg9959. doi: 10.1126/sciadv.adg9959.
Wilson TL, Kim H, Chou CH, Langfitt D, Mettelman RC, Minervina AA, Allen EK, Metais JY, Pogorelyy MV, Riberdy JM, Velasquez MP, Kottapalli P, Trivedi S, Olsen SR, Lockey T, Willis C, Meagher MM, Triplett BM, Talleur AC, Gottschalk S*, Crawford JC*, Thomas PG* (*shared senior authorship). Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T cell receptor lineages. Cancer Discov 2022 Sep 2;12(9):2098-2119. doi: 10.1158/2159-8290.CD-21-1508
Talleur AC, Qudeimat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman A, Srinivasan A, Velasquez MP, Obeng E, Willis C, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou S, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood B, Pui C-H, Lockey T, Geiger TL, Meagher M, Triplett BM, Gottschalk S. Preferential expansion of CD8+ CD19-CAR T cells post infusion and role of disease burden on outcome in pediatric B-ALL. Blood Adv 2022. Apr 21:bloodadvances.2021006293. doi: 10.1182/bloodadvances.2021006293
Hebbar N, Epperly R, Vaidya A, Thanekar U, Moore SE, Umeda M, Ma J, Patil S, Langfitt D, Huang S, Cheng C, Klco JM, Gottschalk S, Velasquez MP. CAR T cells redirected to cell surface GRP78 display robust anti-AML activity and do not target HPCs. Nat Commun 2022 Jan 31;13(1):587. doi: 10.1038/s41467-022-28243-6
Zebley C, Brown C, Mi T, Fan Y, Alli S, Boi S, Galletti G, Lugli E, Langfitt D, Metais JY, Lockey T, Meagher M, Triplett B, Talleur A, Gottschalk S, Youngblood B. CD19-CAR T cells undergo exhaustion epigenetic programming in patients with acute lymphoblastic leukemia. Cell Rep 2021 Nov 30;37(9):110079. doi: 10.1016/j.celrep.2021.110079.
Lange S, Sands GL, Bell M, Patil S, Langfitt D, Gottschalk S. A chimeric GM-CSF/IL18 receptor to sustain CAR T-cell function. Cancer Discov 2021 Jul;11(7):1661-1671. doi: 10.1158/2159-8290.CD-20-0896
Prinzing B, Zebley CC, Peterson CT, Fan Y, Allo Anido A, Yi Z, Nguyen P, Houke H, Bell M, Haydar D, Brown C, Boi S, Alli S, Crawford JC, Riberdy J, Park J-E, Zhou S, Velasquez MP, DeRenzo C, Lazzarotto CR, Tsai SQ, Vogel P, Pruett-Miller SM, Langfitt D, Gottschalk S*, Youngblood B*, Krenciute G*. (*co-corresponding authors) Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med 2021 Nov 17;13(620):eabh0272. doi: 10.1126/scitranslmed. abh0272.
Prinzing B, Schreiner P, Bell M, Fan Y, Krenciute G, Gottschalk S. MyD88/CD40 signaling retains CAR T-cells in a less differentiated state. JCI Insight 2020 Nov 5;5(21):136093
Key publications between 2010 and 2020
Mata M, Gerken G, Nguyen P, Krenciute G, Spencer MD, Gottschalk S. Inducible activation of MyD88 and CD40 in CAR T-cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov 2017; 7(11):1306-1319
Krenciute G, Brooke LP, Yi Z, Wu MF, Hao L, Dotti G, Balyasnikova IV, Gottschalk S. Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen-loss variants. Cancer Immunol Res 2017 Jul.5(7):571-581
Ahmed N, Brawley V, Bielamowicz K, Hegde M, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu M-F, Liu H, Rooney CM, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-specific Chimeric Antigen Receptor–modified virus-specific T-cells for progressive Glioblastoma: a Phase I dose-escalation Trial. JAMA Oncol 2017 3(8):1094-1101
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. HER2-specific Chimeric Antigen Receptor-modified T cells for the Immunotherapy of HER2-positive Sarcoma. J Clin Oncol 2015.33(15):1688-96
Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WH, Chee CL, Ng J, Kan R, Lim D, Tan SH, Ong WS, Cheung YB, Tan EH, Connolly JE, Gottschalk S*, Toh HC*(*shared senior authorship). Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent Nasopharyngeal Carcinoma. Mol Ther. 2014 Jan.22(1):132-9
Kakarla S, Chow KKH, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S (2013). Anti-tumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013 Aug.21(8):1611-20
Chow KKH, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu M-F, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ahmed N, Gottschalk S. T cells redirected to EphA2 for the Immunotherapy of Glioblastoma. Mol Ther 2013 Mar.21(3):629-37
Shaffer D, Savoldo B, YI Z, Chow KKH, Kakarla S, Spencer D, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011 Apr 21.117(16):4304-4314
Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary Glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010 16(2). 474-85
Louis C, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010 Nov-Dec.33(9):983-90
Last update: August 2024